Skip to main content
RNXT logo

RenovoRx, Inc. (RNXT) Stock Price & Analysis

RenovoRx, Inc. (RNXT) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $1.12 (+7.69%), as of the Nov 18, 2026 trading session; market cap $54.0M.

Educational signal · not a buy or sell recommendation · How to read this

$1.12 +$0.08 (+7.69%) Market Cap $54.0M

RenovoRx, Inc. · RNXT · NASDAQ

RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for solid tumors. Their lead product, RenovoGem, is currently in Phase III clinical trials for locally advanced pancreatic cancer.

Price as of Nov 18, 2026

Key Statistics

21 of 100

MoonshotScore v2 · RenovoRx (RNXT)

Weak
Business Quality Poor (16)
Financial Safety Sound (60)
Valuation Rich (26)
Growth Durability Fading (35)
Momentum Rising (73)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Rich; Growth Durability: Fading; Momentum: Rising.

  • quarterly revenue $266,000 (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z -1.57 · Piotroski F 3

Holding back: weak fundamentals, a rich price

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RNXT (57 recorded, newest six shown)
RecordedScoreBand
28Weak
28Weak
22Weak
22Weak
21Weak
21Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.12
Change on the day+7.69%
Market capitalisation$54.0M—
Price / earnings (trailing)-3.34
Shares traded on the day841.2K

Price & events

Other perspectives

Council score for RenovoRx (RNXT): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Moderate
Valuation Weak
Growth Durability Weak
Momentum Moderate

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is RenovoRx (RNXT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. RenovoRx, Inc. (RNXT) is listed on NASDAQ. It employs 17 people. In Q3 FY2025 it reported revenue of $266,000 and net income of -$3M. The market values it at $54.0M.

2 · Latest results

What do the latest results show for RenovoRx (RNXT)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $266,000. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$266,000-$3M-$0.08 (diluted)
Q4 FY2025$238,000-$3M—
Q1 FY2026$563,000-$4M-$0.09 (diluted)
Q2 FY2026$909,000-$3M-$0.06 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for RenovoRx (RNXT)?

Short answer · as of

The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z -1.57 · Piotroski F 3. Trailing ratios: current ratio 5.65 · earnings yield -28.3% · free-cash-flow yield -26.5%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.57 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does RenovoRx compare with its peers?

Short answer

RenovoRx's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.02 Nov 18, 2026$255M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.96 Nov 18, 2026$186M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.32 Nov 18, 2026$813M63 5-pillar Nov 18, 2026
Indaptus Therapeutics, Inc. (INDP) Same industry, near in market value$3.29 Nov 18, 2026$505M60 5-pillar Nov 18, 2026
Cybin Inc. (HELP) Same industry, near in market value$6.89 Nov 18, 2026$550M60 5-pillar Nov 18, 2026
RenovoRx (RNXT) — this page$1.12$54.0M21

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RNXT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RNXT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about RenovoRx (RNXT)?

Read these with our analysis →

Common Questions About RNXT

These answers are editorial: 1 of these 9 answers is drawn from the RNXT research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for RNXT?

RNXT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for solid tumors.

Is RNXT a good stock to buy?

Stock Expert AI does not rate RNXT buy, sell or hold. RenovoRx, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RNXT stock price today?

The last price recorded for RenovoRx, Inc. (RNXT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for RNXT?

RenovoRx faces significant risks inherent to clinical-stage biotechnology companies. The primary risk is the potential failure of RenovoGem in Phase III clinical trials, which would significantly impact the company's value.

What are the key factors to evaluate for RNXT?

RenovoRx, Inc. (RNXT) holds a MoonshotScore in the low range. RenovoGem is currently in Phase III clinical trials for the treatment of locally advanced pancreatic cancer (LAPC). Not financial advice.

How frequently does RNXT data refresh on this page?

RNXT's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RNXT's recent stock price performance?

RenovoRx, Inc. (RNXT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug-device combination (RenovoGem). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RNXT overvalued or undervalued right now?

RenovoRx, Inc. (RNXT) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of RNXT?

Fractional-share availability for RenovoRx, Inc. (RNXT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 10 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.